We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc.
Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse ...
The last time I wrote about Akero Therapeutics (NASDAQ:AKRO) it was with respect to a Seeking Alpha article entitled as "Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program".
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for ...
An Akero Therapeutics drug in development for the fatty liver disease MASH now has clinical trial results showing the experimental treatment reversed organ scarring, bringing patients back from an ...
Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting ...
Akero Therapeutics Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.
SAN FRANCISCO—Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing ...
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...